CORRECTION OF TRIACYLGLYCEROLS AND FREE FATTY ACIDS IN RAT BILE IN EXPERIMENTAL HEPATIC STEATOSIS

Abstract

The relevance of the scientific study is associated with a substantial spread of hepatic steatosis in domestic animals (up to 40%) and the development of health-threatening complications in the form of cirrhosis of the liver, liver failure, and cancer. The purpose of this study was to determine the corrective effectiveness of the “FLP-MD” dietary supplement based on milk phospholipids in relation to the content of triacylglycerols and free fatty acids in the bile of rats with tetracycline-induced hepatic steatosis. Modelling of the drug form of hepatic steatosis was conducted by intragastric administration of a 4% solution of tetracycline hydrochloride at the rate of 0.5 g/kg of animal body weight for seven days. As a corrective therapy, for nine days the animals were intragastrically administered a dietary supplement “FLP-MD” based on milk phospholipids at a dose of 13.5 mg/kg of body weight. At the end of the experiment, bile samples were taken from rats for three hours every 30 minutes, in which the content of triacylglycerols and free fatty acids was determined by thin-layer chromatography. It was determined that the concentration of triacylglycerols in the bile of sick rats at the third hour of its selection is 63.0% lower than the control indicators. In laboratory rats that received a phospholipid-containing supplement against the background of modelling drug-induced hepatosis, this indicator in bile corresponded to the values of the control group. Therewith, the concentration of free fatty acids in bile samples at the third hour of its selection in sick rats was marked by a decrease of 47.2% compared to the control. The use of the dietary supplement under study in sick animals caused an increase in the concentration of free fatty acids in bile by 2.85 times compared to the control, which reduces the intensity of their use for the synthesis of triacylglycerols and prevents the development of fatty liver infiltration. Therefore, the phospholipid-containing dietary supplement is a highly effective corrective agent for impaired metabolism of triacylglycerols and free fatty acids in rats with drug-induced hepatic steatosis. This gives grounds to recommend it as a corrective therapy and for the prevention of the development of hepatic steatosis, especially in the case of the use of tetracycline antibiotics in animals